Optimist Retirement Group LLC Sells 1,153 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Optimist Retirement Group LLC lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.2% during the fourth quarter, HoldingsChannel reports. The firm owned 26,081 shares of the biopharmaceutical company’s stock after selling 1,153 shares during the quarter. Gilead Sciences makes up 1.1% of Optimist Retirement Group LLC’s investment portfolio, making the stock its 18th largest position. Optimist Retirement Group LLC’s holdings in Gilead Sciences were worth $2,409,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Avior Wealth Management LLC raised its position in Gilead Sciences by 1.2% during the third quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock worth $782,000 after acquiring an additional 108 shares in the last quarter. Southland Equity Partners LLC raised its holdings in shares of Gilead Sciences by 3.6% in the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 110 shares during the period. Concord Asset Management LLC VA lifted its stake in Gilead Sciences by 3.8% in the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 111 shares during the last quarter. Berkshire Bank grew its holdings in Gilead Sciences by 3.4% during the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 111 shares during the period. Finally, TFB Advisors LLC increased its position in Gilead Sciences by 1.2% during the third quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock worth $788,000 after buying an additional 116 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $99.65 on Thursday. The firm has a 50 day moving average of $92.71 and a 200-day moving average of $86.32. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $100.51. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The stock has a market capitalization of $124.19 billion, a PE ratio of 1,107.22, a PEG ratio of 1.37 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company’s revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the business earned $2.29 earnings per share. On average, equities research analysts predict that Gilead Sciences, Inc. will post 4.34 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on GILD. Cantor Fitzgerald reiterated a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Sanford C. Bernstein initiated coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price objective on the stock. Oppenheimer lifted their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Finally, Daiwa America raised shares of Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $98.39.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 142,180 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 572,824 shares of company stock valued at $53,611,715. Corporate insiders own 0.29% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.